Talzenna .35 mg/1

Talzenna .35 mg/1 is a liquid-filled capsule containing talazoparib, used for targeted therapy. This medication is designed for oral administration and is available in a 30-capsule bottle.

Talzenna .35 mg/1 is primarily used in the treatment of certain types of cancer. Talazoparib is a PARP inhibitor, which works by targeting specific enzymes involved in DNA repair. This medication is often prescribed for patients with specific genetic mutations that affect DNA repair mechanisms. What is Talzenna used for? It is typically used in the management of advanced or metastatic cancer in patients who have certain genetic markers.

Common effects of Talzenna .35 mg/1 may include fatigue, nausea, and anemia. Some patients may experience vomiting, decreased appetite, and hair loss. It is important to monitor for any unusual symptoms and consult a healthcare provider if severe side effects occur.

Talzenna .35 mg/1 should be handled with care and stored as directed. It is essential to follow the prescribed dosage and administration instructions. Patients should inform their healthcare provider about any existing medical conditions or allergies before starting this medication. Pregnant women or those planning to become pregnant should discuss the potential risks with their doctor.

Talzenna .35 mg/1 may interact with certain medications, including those that affect liver enzymes. It is important to inform your healthcare provider about all medications you are taking, including over-the-counter drugs and supplements. Alcohol consumption should be avoided unless advised otherwise by a healthcare professional.